Published online Mar 16, 2021. doi: 10.12998/wjcc.v9.i8.1885
Peer-review started: September 23, 2020
First decision: December 31, 2020
Revised: January 10, 2021
Accepted: January 25, 2021
Article in press: January 25, 2021
Published online: March 16, 2021
Processing time: 163 Days and 1.8 Hours
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) involvement in the central nervous system (CNS) is particularly rare. SPTCL with CNS involvement has an exceedingly poor prognosis, and no optimum therapeutic method has been discovered. To the best of our knowledge, this is the first reported case of SPTCL invading the CNS achieving long-term remission with lenalidomide maintenance therapy.
A 63-year-old man diagnosed with SPTCL was admitted to the hospital with severe headache for 15 d after four cycles of chemotherapy. Subsequent to the treatment, the patient developed CNS involvement. Craniotomy biopsy was pathologically diagnosed as CNS T-cell lymphoma, and two courses of chemotherapy were performed postoperatively. Due to the intolerance of the side effects of chemotherapeutic drugs, the patient received lenalidomide instead. The magnetic resonance imaging of the head at the 8 mo follow-up indicated no signs of recurrence, and the vital signs were stable.
Lenalidomide deserves further investigation as a targeted drug for SPTCL cases involving the CNS.
Core Tip: Subcutaneous panniculitis-like T-cell lymphoma is a rare peripheral T-cell lymphoma that occurs primarily in the skin. We present a special case of central nervous system T-cell lymphoma secondary to subcutaneous panniculitis-like T-cell lymphoma. Lenalidomide deserves further investigation as a targeted drug for subcutaneous panniculitis-like T-cell lymphoma cases involving the central nervous system.
